David Cohen Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Cohen KDMN stock SEC Form 4 insiders trading

David has made over 10 trades of the Kadmon Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of KDMN stock worth $28,500 on 12 June 2019.

The largest trade he's ever made was exercising 3,000 units of Kadmon Inc stock on 12 June 2019 worth over $28,500. On average, David trades about 540 units every 33 days since 2015. As of 12 June 2019 he still owns at least 35,682 units of Kadmon Inc stock.

You can see the complete history of David Cohen stock trades at the bottom of the page.

David Cohen biography

Dr. David Eric Cohen, M.D. is Independent Director of the Company. Dr. Cohen is the Charles C. and Dorothea E. Harris Professor of Dermatology at New York University School of Medicine, where he also serves as Chief of Allergy and Contact Dermatitis, Vice Chairman of Clinical Affairs, and Director of Occupational and Environmental Dermatology. Dr. Cohen joined the NYU faculty in 1994 and his work has concentrated on cutaneous allergic and toxic reactions to exogenous and photo-reactive chemicals and the interaction of environmental stressors on the skin. Dr. Cohen has previously served as a lecturer of Environmental Sciences at Columbia University School of Public Health since 1993 and has served as an Affiliated Faculty Member of the NYU Global Institute of Public Health since 2014. Dr. Cohen served on the board of directors of Dermira from 2014 until its acquisition by Eli Lilly and Company in 2020 and had previously served as a scientific advisor to Dermira since its inception in 2010. Dr. Cohen also served on the Boards of Vyteris from 2011 to 2012 and Connetics from 2005 until its acquisition by Stiefel in 2006. Dr. Cohen is the Past President of the American Dermatological Association, and served as President of the American Contact Dermatitis Society, the Dermatology Section of the New York Academy of Medicine, and the New York Dermatological Association. Dr. Cohen served as a founding board member for the American Acne and Rosacea Society, and led the national guidelines of care for individuals with Latex allergy and served on the panel to establish the national guidelines of care for Atopic Dermatitis for the American Academy of Dermatology. Dr. Cohen received a B.S. in biomedical science from the City University of New York, an M.D. from State University of New York at Stony Brook School of Medicine and an M.P.H. in environmental science from Columbia University School of Public Health.

What is the salary of David Cohen?

As the Independent Director of Kadmon Inc, the total compensation of David Cohen at Kadmon Inc is $299,229. There are 6 executives at Kadmon Inc getting paid more, with Harlan Waksal having the highest compensation of $4,742,770.

How old is David Cohen?

David Cohen is 55, he's been the Independent Director of Kadmon Inc since 2019. There are 6 older and 3 younger executives at Kadmon Inc. The oldest executive at Kadmon Holdings Inc is Eugene Bauer, 77, who is the Independent Director.

What's David Cohen's mailing address?

David's mailing address filed with the SEC is C/O KADMON HOLDINGS, INC., 450 E. 29TH STREET, NEW YORK, NY, 10016.

Insiders trading at Kadmon Inc

Over the last 8 years, insiders at Kadmon Inc have traded over $7,020,661 worth of Kadmon Inc stock and bought 7,084,916 units worth $54,943,934 . The most active insiders traders include Advisors Llcperceptive Life..., Asset Management Lp Golden ... et Daniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,948,175. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth $46,880.

What does Kadmon Inc do?

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Kadmon Inc executives and stock owners

Kadmon Inc executives and other stock owners filed with the SEC include:

• Harlan Waksal,
  President, Chief Executive Officer, Director
• Steven Meehan,
  Chief Financial Officer, Executive Vice President
• Gregory Moss,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Dr. Harlan W. Waksal,
  Pres, CEO & Director
• Gregory S. Moss Esq.,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Arthur Kirsch,
  Independent Director
• David Cohen,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Eugene Bauer,
  Independent Director
• Tasos Konidaris,
  Non-Executive Independent Chairman of the Board
• Ellen Cavaleri,
  IR Contact Officer
• Nancy Miller-Rich,
  Director
• John Ryan,
  Executive Vice President, Chief Medical Officer
• Dr. Simon Cooper,
  Sr. VP & Chief Medical Officer
• Haya Taitel M.S., R.Ph.,
  Sr. VP & Chief Commercial Officer
• Sanjay Aggarwal,
  Sr. VP of Clinical Devel.
• Kyle Carver,
  Sr. VP, Chief Accounting Officer & Controller
• Charles Darder,
  Principle Accounting Officer
• Asset Management Lp Golden ...,
  
• D. Dixon Boardman,
  
• Konstantin Poukalov,
  EVP, Chief Financial Officer
• Alexandria Forbes,
  
• Andrew B Cohen,
  
• I, Llc Kadmon,
  
• Susan Wiviott,
  
• Shengda Zan,
  
• Thomas E Shenk,
  
• Steven N. Gordon,
  Exec VP, GC, Chief Admin, Comp
• Lawrence Kenneth Cohen,
  Exec. VP, Business Develop.
• Daniel S Third Point Llc Loeb,
  
• Bart M Schwartz,
  
• Advisors Llcperceptive Life...,
  
• Kyle Carver,
  SVP, CAO, Controller
• Cynthia Louise Flowers,
  Director